Atif Collins, MD
Ophthalmic Plastic and Reconstructive Surgery · Fresno, CANPI 1891010948
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,875 of the $3,775 with a category attached, or 76.2%. Genentech, Inc. accounts for 76.9% of it on its own, with 4 other manufacturers making up the rest. 2025 is the largest year on record at $3,068, more than ten times the $62 reported in 2019.
Across 30 payments — averaging $125.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$3K
- Amgen$596
- AbbVie$163
- Bausch & Lomb, A Division Of Bausch Health US, LLC$62
- Galderma Laboratories, L.p.$51
Across 8 payments — averaging $632.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$5K
What the payments were for
- Consulting fees$2,87576%
- Food & beverage$90024%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 3 | $2,903 |
| Amgen(2 entities) | 21 | $596 |
| AbbVie | 2 | $163 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $62 |
| Galderma Laboratories, L.p. | 3 | $51 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,775 in reported general payments places this provider in the 65th percentile of 50 ophthalmic plastic and reconstructive surgery providers in California.
See all ophthalmic plastic and reconstructive surgery providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErythromycinErythromycin Base | 257 | $3,618 |
| Doxycycline Monohydrate | 37 | $1,451 |
| Cyclosporine | 13 | $1,190 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 49 | $568 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 12 | $519 |
| Metronidazole | 30 | $511 |
| Doxycycline Hyclate | 24 | $279 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 26 | $241 |
| Fluticasone Propionate | 13 | $207 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 12 | $182 |
| Lorazepam | 21 | $101 |
| Amoxicillin | 17 | $100 |
Paid to pharmacies, not to this prescriber.
Other ophthalmic plastic and reconstructive surgery in Fresno
- Frank WaldropFresno$2K
- Marjan FaridIrvine$742K
- Jeffrey JosephNewport Beach$292K
- Sandy Zhang-NunesLos Angeles$149K
- Soheab UgradarLos Angeles$131K
- Andrea KosslerStanford$91K
- Nicolas BiroWest Covina$76K
- Joseph ChangBakersfield$74K
- Anupam JayaramMenlo Park$26K
- Charles KimStockton$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.